No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
WST West Pharmaceutical Services
- 323.770
- +7.590+2.40%
Close Jul 24 16:00 ET
- 330.000
- +6.230+1.92%
Post 17:50 ET
23.58BMarket Cap42.71P/E (TTM)
325.010High312.680Low1.04MVolume317.770Open316.180Pre Close335.11MTurnover1.44%Turnover Ratio41.09P/E (Static)72.84MShares415.02752wk High8.80P/B23.42BFloat Cap309.89552wk Low0.78Dividend TTM72.35MShs Float472.351Historical High0.24%Div YieldTTM3.90%Amplitude3.190Historical Low322.154Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
West Pharmaceutical Q2 2024 Earnings Preview
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
A Look At The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Does West Pharmaceutical Services (WST) Have Attractive Growth Drivers?
Stephens Adjusts Price Target on West Pharmaceutical Services to $400 From $420
Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Comments
RECAP
U.S. equity indexes rose after Thursday, with the $Nasdaq Composite Index(.IXIC.US$ lagging the pack, as investors weighed retail sales and jobless claims ahead of more inflation data this week.
The $S&P 500 Index(.SPX.US$ rose 0.58% to 5,029, a new closing high with the $Dow Jones Industrial Average(.DJI.US$ up 0.91% to 38,664. The $Nasdaq Composite Index(.IXIC.US$ was moderately higher at 15,906, af...
U.S. equity indexes rose after Thursday, with the $Nasdaq Composite Index(.IXIC.US$ lagging the pack, as investors weighed retail sales and jobless claims ahead of more inflation data this week.
The $S&P 500 Index(.SPX.US$ rose 0.58% to 5,029, a new closing high with the $Dow Jones Industrial Average(.DJI.US$ up 0.91% to 38,664. The $Nasdaq Composite Index(.IXIC.US$ was moderately higher at 15,906, af...
41
5
Analysts worry about the company's shifting tone and the enduring effect of clients' inventory management on West's finances. Doubts also arise about the company's demand visibility and if current trends suggest a fundamental issue in West's base business.
Jefferies analyst David Windley sees FDA approvals of GLP-1s for obesity treatment as a huge opportunity for the manufacturing supply chain. He also notes high rivalry in the injectable fill/finish market. Windley upgraded West Pharmaceutical to Buy, raising its price target by 66% to $536, citing its global footprint and capacity to meet growing GLP-1s demand.
The market sentiment around West Pharmaceutical Services hasn't changed much over the past five years, with the share price seemingly reacting to the EPS. The recent improvement in TSR could indicate that the business is getting better with time.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg